Characterization of Driver Mutations in Anaplastic Thyroid Carcinoma IdentifiesRASandPIK3CAMutations as Negative Survival Predictors

doi:10.3390/cancers12071973

CNU IR > Pharmacy and Science > Dept. of Cosmetic Science and institute of cosmetic science > Periodical Articles > Item 310902800/34099

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/34099

Title:	Characterization of Driver Mutations in Anaplastic Thyroid Carcinoma IdentifiesRASandPIK3CAMutations as Negative Survival Predictors
Authors:	Lai, Wei-An Liu, Chih-Yi Lin, Shih-Yao Chen, Chien-Chin Hang, Jen-Fan
Contributors:	Taipei Vet Gen Hosp, Dept Pathol & Lab Med Sijhih Cathay Gen Hosp, Div Pathol Far Eastern Mem Hosp, Dept Pathol Ditmanson Med Fdn Chia Yi Christian Hosp, Dept Pathol Chia Nan Univ Pharm & Sci, Dept Cosmet Sci Natl Yang Ming Univ, Sch Med
Keywords:	anaplastic thyroid carcinoma RAS BRAF(V600E) PIK3CA TERTpromoter TP53
Date:	2020
Issue Date:	2022-11-18 11:23:52 (UTC+8)
Publisher:	Mdpi
Abstract:	Anaplastic thyroid carcinoma (ATC) is rare but highly aggressive. We investigated the association of selected driver mutations, includingBRAF,RAS,PIK3CA,TERTpromoter,TP53,POLE, and mismatch repair deficiency (MMR-D) with the clinicopathological features of ATC to identify prognostic and predictive biomarkers. Thirty-nine retrospective cases from pathology archives were enrolled for clinicopathology analysis and immunohistochemistry, and 27 cases had sufficient specimens for further molecular testing using targeted next-generation sequencing and mass spectrometry.BRAF(V600E)andRASmutations were identified in 25.9% and 40.7% of ATC, respectively.BRAF(V600E)mutation was significantly associated with coexisting papillary thyroid carcinoma (p= 0.009) andRASmutations with female gender (p= 0.012). In univariant analysis, the non-BRAF/RAStumors were significantly associated with the presence of a sarcomatoid pattern (p= 0.045).PIK3CA,TERTpromoter, andTP53mutations were identified in 14.8%, 81.5%, and 70.4% of cases, respectively. No MMR-D orPOLEmutations were detected. In survival analyses,RASandPIK3CAmutations were significantly associated with inferior outcomes (p= 0.03 andp= 0.006, respectively). In conclusion, driver mutations in ATC are associated with distinct clinicopathological features.RASandPIK3CAmutations were negative predictors for patient survival. Emerging therapeutic agents targeting BRAF, RAS, and PI3 kinase may benefit a substantial proportion of ATC patients.
Relation:	Cancers, v.12, n.7, pp.13
Appears in Collections:	[Dept. of Cosmetic Science and institute of cosmetic science] Periodical Articles

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	447	View/Open

Loading...